Hypertonic Saline Therapy Reshapes Infant Nasal Microbiome and Fuels Resistant Pathogens
A landmark infant nasal microbiome atlas reveals that hypertonic saline inhalation accelerates dangerous pathogen growth and antibiotic tolerance.
Summary
Researchers built the first comprehensive gene atlas of the infant nasal microbiome using 704 longitudinal nasal swabs from infants with and without cystic fibrosis. They discovered that inhaled hypertonic saline — a common CF treatment — significantly alters the microbial community, promoting the expansion of salt-tolerant opportunistic pathogens like Haemophilus influenzae and fungi. Lab experiments confirmed that hypertonic saline accelerates H. influenzae growth and triggers efflux pumps associated with antibiotic resistance. These findings raise important questions about the unintended microbial consequences of a widely used respiratory therapy, and provide a valuable reference framework for future airway microbiome research.
Detailed Summary
The nasal airway microbiome in early life plays a critical role in respiratory health, immune development, and susceptibility to infection. Yet how common medical interventions alter this microbial ecosystem — especially in vulnerable infants — has been poorly understood until now.
Researchers from the Broad Institute of MIT and Harvard, along with Swiss pediatric pulmonology teams, performed metagenomic sequencing on 704 longitudinal nasal swabs collected from infants with and without cystic fibrosis (CF). From this data, they constructed a non-redundant infant nasal microbial gene atlas — a comprehensive functional and compositional reference map of the early-life airway microbiome.
The central finding is striking: inhaled hypertonic saline, routinely used in CF to improve mucociliary clearance, drives significant shifts in the nasal microbiome. Specifically, it promotes the expansion of salt-associated transporter genes and favors opportunistic pathogens — most notably Haemophilus influenzae and certain fungi — that carry these transporter genes with high sequence and structural identity. In vitro experiments confirmed that hypertonic saline accelerates H. influenzae growth and induces efflux pumps linked to antibiotic tolerance, a mechanism that could complicate future infection management.
These results carry meaningful clinical implications. Hypertonic saline is considered a safe, non-pharmacological intervention, but this study suggests it may inadvertently select for more resilient, antibiotic-tolerant pathogens in the airway. Clinicians managing CF and other respiratory conditions should be aware of these potential microbial trade-offs.
Important caveats apply. The summary is based on the abstract only, as the full paper is not open access. The study population is specific to infants with and without CF, limiting generalizability to older patients or other conditions. Additionally, in vitro findings may not fully replicate the complex in vivo airway environment.
Key Findings
- Hypertonic saline inhalation in CF infants expands salt-tolerant opportunistic pathogens including Haemophilus influenzae and fungi.
- Hypertonic vs. isotonic saline accelerates H. influenzae growth and induces antibiotic-tolerance efflux pumps in vitro.
- A novel infant nasal microbial gene atlas was constructed from 704 longitudinal metagenomic samples.
- Salt-associated transporter genes identified in the atlas show high sequence identity across multiple CF-associated pathogens.
- Findings establish a reference framework for studying how therapies perturb the early-life airway microbiome.
Methodology
The study used metagenomic sequencing of 704 longitudinal nasal swabs from infants with and without cystic fibrosis to build a non-redundant gene atlas. Functional and compositional microbiome changes were analyzed in relation to inhalation therapy type. In vitro experiments tested the effects of hypertonic versus isotonic saline on H. influenzae growth and efflux pump expression.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting depth of methodological and statistical assessment. The study population is restricted to infants with and without CF, so findings may not generalize to adults or other respiratory conditions. In vitro results regarding H. influenzae growth and efflux pump induction require validation in clinical or animal models.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.